Ahmad Tarhini, M.D./Ph.D.
Department of Medicine
University of Pittsburgh
HCC, Room 555
5150 Centre Avenue
Pittsburgh, PA 15232
A major objective of my research is the testing of immunologic and genetic biomarkers and determinants of outcome in patients with melanoma, as well as predictors of response to biotherapeutic agents. In addition, I pursue studies that test novel targeted therapeutic strategies selected based upon our continuously deepening understanding of the molecular circuitry, immune checkpoints, and immunobiology of melanoma. I work in collaboration with colleagues both nationally and internationally through US cooperative group mechanisms such as the US intergroup E1609 trial, an international study wherein we are testing adjuvant ipilimumab, an immune checkpoint blocking antibody, at high and standard dose levels in comparison to the current standard of care, interferon-alpha. This trial, which I am chairing through the ECOG-ACRIN cooperative group, also forms the basis of a major biomarker project that is planned to identify predictive markers of therapeutic benefit to ipilimumab and interferon-alpha.
Tarhini AA, Butterfield L, Kalinski P, Shuai Y, Gooding WE, Kirkwood JM (2012). Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunotherapy 35: 702-710.
Tarhini AA, Leng S, Moschos S, Lin Y, Gooding W, Yin Y, Sander S, Kirkwood JM (2012). Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunotherapy 35: 359-366.
Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM (2012). Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 30: 322-328.
Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A, Kirkwood JM (2011). Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res. 15: 6574-6581.